Zuranolone

Brand names: Zurzuvae · Active ingredient: Zuranolone

In short: ZURZUVAE is indicated for the treatment of postpartum depression (PPD) in adults.

Forms & strengthsCapsules: 20 mg: light-orange cap, ivory to light-yellow body, printed with “S-217 20mg” on body of capsule in black 25 mg: light-orange cap, light-orange body, printed with “S-217 25mg” on body of capsule in black 30 mg: orange cap, light-orange body, …
LabelBiogen MA Inc.
Label updatedJun 17, 2026

What is Zuranolone used for?

ZURZUVAE is indicated for the treatment of postpartum depression (PPD) in adults.

⚠ Boxed warning (FDA's strongest warning)

ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects

.

Advise patients not to drive or engage in other potentially hazardous activities until at least 12 hours after ZURZUVAE administration for the duration of the 14-day treatment course. Inform patients that they may not be able to assess their own driving competence, or the degree of driving impairment caused by ZURZUVAE

.

Zuranolone dosage

The recommended dosage of ZURZUVAE is 50 mg taken orally once daily in the evening for 14 days. Administer ZURZUVAE with fat-containing food (e.g., 400 to 1,000 calories, 25% to 50% fat) . If patients experience CNS depressant effects within the 14-day period, consider reducing the dosage to 40 mg once daily in the evening within the 14-day period.

ZURZUVAE can be used alone or as an adjunct to oral antidepressant therapy.

The safety and effectiveness of ZURZUVAE use beyond 14 days in a single treatment course have not been established.

CYP3A4 Inducers

Avoid concomitant use of ZURZUVAE with CYP3A4 inducers .

CYP3A4 Inhibitors

Reduce the ZURZUVAE dosage to 30 mg orally once daily in the evening for 14 days when used concomitantly with a strong CYP3A4 inhibitor . No dosage modification is recommended when ZURZUVAE is concomitantly used with a moderate CYP3A4 inhibitor.

The recommended dosage of ZURZUVAE in patients with severe hepatic impairment (Child-Pugh C) is 30 mg orally once daily in the evening for 14 days . The recommended dosage in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment is the same as those in patients with normal hepatic function.

The recommended dosage of ZURZUVAE in patients with moderate or severe renal impairment (eGFR <60 mL/min/1.73 m2) is 30 mg orally once daily in the evening for 14 days .

The recommended dosage in patients with mild renal impairment (eGFR 60 to 89 mL/min/1.73 m2) is the same as those in patients with normal renal function.

If a ZURZUVAE evening dose is missed, take the next dose at the regular time the following evening. Do not take extra capsules on the same day to make up for the missed dose. Continue taking ZURZUVAE once daily until the remainder of the 14-day treatment course is completed.

How to take Zuranolone — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Impaired Ability to Drive or Engage in Other Potentially Hazardous Activities

Inform patients that ZURZUVAE causes driving impairment. Advise patients to take ZURZUVAE in the evening. Advise patients not to drive a motor vehicle or engage in other potentially hazardous activities requiring complete mental alertness, such as operating machinery, until at least 12 hours after ZURZUVAE administration. Warn patients that they may not be able to assess their own ability to drive or the degree of impairment caused by ZURZUVAE .

Central Nervous System Depressant Effects

Inform patients that ZURZUVAE can cause somnolence, dizziness, sedation, and confusion. Advise patients to use caution if taking ZURZUVAE in combination with alcohol, other CNS depressants, or medications that increase the concentration of ZURZUVAE .

Suicidal Thoughts and Behavior

Advise patients to look for the emergence of suicidal thoughts and behaviors and instruct them to report such symptoms to the healthcare provider immediately .

Administration Instructions

Inform patients to take ZURZUVAE with fat-containing food . …

Warnings & precautions

Do not take this medicine if: None.

ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects . In two driving simulation studies, the driving ability of healthy adults was impaired in a dose-dependent manner following repeat nighttime administration of 30 mg of ZURZUVAE (0.6 times the recommended dose) for 5 days as well as 50 mg of ZURZUVAE (recommended dose) for 7 days .

Advise patients not to drive a motor vehicle or engage in other potentially hazardous activities requiring complete mental alertness, such as operating machinery, until at least 12 hours after ZURZUVAE administration for the duration of the 14-day treatment course. Inform patients that they may not be able to assess their own driving competence or the degree of driving impairment caused by ZURZUVAE.

ZURZUVAE can cause CNS depressant effects such as somnolence and confusion.

In Study 1, 36% of patients who received 50 mg of ZURZUVAE and 6% of patients who received placebo daily developed somnolence. In Study 2, 19% of patients who received another zuranolone capsule formulation (approximately equivalent to 40 mg of ZURZUVAE) and 11% of patients who received placebo daily developed somnolence . In each clinical study, some ZURZUVAE-treated patients developed confusional state. One of these cases was severe, and was also associated with somnolence, dizziness, and gait disturbance. A higher percentage of ZURZUVAE-treated patients, compared to placebo-treated patients, experienced somnolence, dizziness, or confusion that required dosage reduction, interruption, or discontinuation .

Because ZURZUVAE can cause CNS depressant effects, patients may be at higher risk of falls. …

Zuranolone side effects

The following adverse reactions are discussed in more detail in other sections of the labeling:

Impaired Ability to Drive or Engage in Other Potentially Hazardous Activities

Central Nervous System Depressant Effects

Suicidal Thoughts and Behavior

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of ZURZUVAE for the treatment of postpartum depression (PPD) was evaluated in two placebo-controlled clinical studies in 347 women with PPD treated with 50 mg of ZURZUVAE (Study 1), or with another zuranolone capsule formulation approximately equivalent to 40 mg of ZURZUVAE (Study 2) once daily for 14 days . The studies included adult patients 18 to 44 years of age diagnosed with PPD.

Across PPD clinical studies at all doses studied (Studies 1 and 2), serious adverse reactions included confusional state (1%) .

In Study 1, the incidence of adverse reactions that led to discontinuation in patients treated with 50 mg of ZURZUVAE and placebo was 2% and 1%, respectively. The most common adverse reaction leading to treatment discontinuation in ZURZUVAE-treated patients was somnolence.

Dosage reduction due to an adverse reaction occurred in 16% of ZURZUVAE-treated patients. …

Drug interactions

Table 4 displays clinically important drug interactions with ZURZUVAE.

CNS Depressant Drugs and Alcohol

Clinical Impact | Due to additive pharmacological effects, the concomitant use of CNS depressant drugs, including alcohol, may increase impairment of psychomotor performance or CNS depressant effects.

Management | If use with another CNS depressant is unavoidable, consider dosage reduction. Caution should be used when ZURZUVAE is administered in combination with other CNS drugs or alcohol .

Strong CYP3A4 Inhibitors

Clinical Impact | Concomitant use of ZURZUVAE with a strong CYP3A4 inhibitor increases the exposure of zuranolone , which may increase the risk of ZURZUVAE-associated adverse reactions.

Management | Reduce the ZURZUVAE dosage when used with a strong CYP3A4 inhibitor .

CYP3A4 Inducers

Clinical Impact | Concomitant use of ZURZUVAE with a CYP3A4 inducer decreases the exposure of zuranolone , which may reduce the efficacy of ZURZUVAE.

Management | Avoid concomitant use of ZURZUVAE with CYP3A4 inducers .

About this medicine

ZURZUVAE contains zuranolone, a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator. The chemical name is 1-[(3α, 5β)-3-hydroxy-3-methyl-20- oxo-19-norpregnan-21-yl]-1H-pyrazole-4-carbonitrile and it has the following chemical structure:

The molecular formula of zuranolone is C25H35N3O2 and the relative molecular mass is 409.57 Da.

Zuranolone is a white to off-white, non-hygroscopic, crystalline solid. It is sparingly soluble in ethyl acetate, methanol, and ethanol; slightly soluble in methyl tert-butyl ether and isopropanol; soluble in tetrahydrofuran and acetone; and practically insoluble in water and n-heptane.

ZURZUVAE is available in 20 mg, 25 mg, and 30 mg capsules for oral administration. Each capsule contains zuranolone as the active ingredient and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, mannitol, microcrystalline cellulose, and sodium stearyl fumarate. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f18e53b0-d0bb-422d-8de7-ab64b7292b29. Read the full official label on DailyMed.

Related medicines

Sertraline Escitalopram Bupropion Fluoxetine Trazodone Duloxetine Prednisone Buspirone